1.png)
Correlation of diuretic therapy toward clinicaloutcomeof patients suffering from chronic kidney disease hospitalized in RSUP DR. M. Djamil Padang
Abstract
ABSTRACT
Kidney is one of the most important organs of the human body. The goal of diuretic therapy is to reduce edema in patients with impaired renal function. The therapy of diuretic is very important, because the therapy is effective to control of the volume of extracellular fluid, reduce protein exretion in urine and reduce on effects of hyperceluler complications. The purpose of this research is to provide information on the effect of giving diuretics with clinical outcome of patient with cronic kidney disease. The research was conducted by using longitudinal observational study design. Longitudinal observation is a method that perform data retrieval by a prospective census method with daily follow up until patient returns. The result of research showed that the most widely used diuretic was furosemide. Then the results also showed improvement of blood pressure, pulse, respiration rate, creatinine and urea although the results were not statistically significally (p>0.05). Mortality rate of the subjects in RSUP DR. M.Djamil Padang Hospital was very small. Patient with diuretic and without diuretic have equal mortality rate (p>0.05).
Keyword: Kidney, CKD, Outcome, DiureticKeywords
Full Text:
PDFReferences
Alam S. & I. Hadibroto. 2007. GagalGinjal. Jakarta: PT GramediaPustakaUtamaAnggota IKAPI.
Allan H.L. 2013. Phamacotherapy Review Program for Advenced Clinical Pharmacy Practice. Kansas. Unites Stated of America: American collage of clinical pharmacy lenexa.
Allan J.C. 2009. CKD and The Public Agenda for Chronic Disease. Kansas. Unites Stated of America Collage of Clinical Pharmacy Lenexa.
Andrew D.R., E.J. Bergstralh, L.J. Melton, X. Li, & A.L. Weaver. 2009. Kidney Stone and Risk for Chronic Kidney Disease. Clin.J.Am.Soc.Nephrol. 4: 804-811.
Bakris G.I., M.R. Weir, S. Shanifar, Z. Zhang, & J. Douglas. 2003. Effect of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch. Intern.Med. 163: 1555-1565.
Baradero, M., Mary W.D., danYakobus S., 2009, Seri Asuhan Keperawatan Klien Gangguan Ginjal, Penrbit Buku Kedokteran : EGC, Jakarta.
Bianchi S., Bigazzi, & V.M. Campese. 2006. Long-term Effect of Spironolacton on Proteinuria and Kidney Function in Patients with Chronic Kidney Disease. Kidney.Int. 70: 2116-2123.
Chris. 2007. At Glance SistemGinjal.Edisikedua. Jakarta: Erlangga.
Dipiro J.T., B.G. Wells, T.L. Scwinghammer, & C.V. Dipiro. 2009. Pharmacotherapy Handbook seventeditionI. New York: McGraw Hill Companies.
Drey N., P. Roderick, M. Mulle, & M. Rugerson. 2003. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease.Am.J,Kidney.Dis. 42 (4): 677-684.
Dussol B., J.M. Frances S. Morange, C.D.delpero, & O. Mundler.2005. A Randomized Trial of Furosemid vs Hydrochlorthiazide in Patients with Chronic Renal Failure and Hypertention. Nephrol.Dial.Transplant. 20: 349-353.
Egberongbe A.A., V.A. Adetiloye, A.O. Adeyinka, O.T. Afolabi, & A.O. Akintomade. 2010. Evaluation of Renal Volume by Ultrasonography in Patients with Essential Hypetention in Iie-Ife. South Western Nigeria.Libyan.J.Med. 5: 4848-4814.
Epstein M. 2001. Aldosteron as a Determinant of Cardiovaskular and Renal Dysfunction. J.R.Soc.Med. 94: 378-383.
Ernst M.E. & J.A. Gordon. 2010. Diuretic Therapy: Key Aspect in Hypertention and Renal Disease. J.Nephrol. 23: 487-493.
Gaber O.A. 2011. Addressing Chronic Kidney Disease in Texas, The Report of the Chronic Kidney Disease Task Force. United Stated: Departement of State Health Services.
Garg A.X., A. Papaioannou, N. Ferko, G. Campbell, & J.A. Clarker. 2004. Estimating The Prevalence of Renal Insuficiency in Seniors Requiring Long-term Care.Kidney.Int. 65: 649-653.
Gibney J. 2005. Regional Development Agencies and Bussiness Change. Astigate: Aldhershot.
Goligorsky S.M. 2005. Reassessing Treatment of Acute Heart Failure Syndrome: The ADHERE Registry.Eur.Heart.J. 7: 13-19.
Jerry Y. 2011. Chronic Kidney Disease: Clinical Practice Recommendations for Primary Car Physicians and Healthcare Providers. A Collaborative Approach. Edition 6. California. Los Angeles. Henry Ford Medical Group.
Jha V, Garcia-Garcia G, Iseki K et al., 2013, Chronic kidney disease: global dimension and perspectives, The Lancet, 382(9888):260-272.
Kenward R.L. & C.K. Tan. 2003. Penggunaan Obat pada Gagal Ginjal. In Aslam M., C.K. Tan & A.I. Prayitno. Farmasi Klinis Menuju Pengobatan Rasional dan Penghargaan Pilihan Pasien. Jakarta: PT Elex Media Komputindo.
Kim, S., C.S. Lim, D.C. Han, G.S. Kim, H. J. Chin, S.J. Kim, et al., 2009, The Prevalence of Chronic Kidney Disease (CKD) and the Associated Factor to CKD in Urban Korea; A Population-based Cross-sectional Epidemiologic Study, J Korean Med Sci, 24(suppl 1): s11-21.
Kumar V., A.K. Abbas, & N. Fausto. 2005. Hypertensive Vascular Disease: Robn and Cotran Pathologic Basis of Disease. 7th Edition.Philadelpia: Elseiver Saunders.
Kumboyono L., Supriati, & R. Roesardhyati. 2010. Hubungan Persepsi Keparahan Penyakit dengan Kepatuhan Minum Obat pada Pasien Hipertensi di Poliklinik Jantung Rumah Sakit Umum Daerah Dr.Saiful Anwar Malang. Bandung: Majalah Kesehatan. FKUB.
Lemeire N., W.V. Biesen, & R. Vanholder. 2006. The Rise of Prevalence and The Fall of Mortality of Patients with Acute Renal Failure: What the Analysis of Two Databases Does and Does Not Tell Us. J.Am.Soc.Nephrol. 17: 923-925.
Maura R., R. Michela, D. Luca, V. Simone, & D. Giacorno. 2006. Importance of Blood Pressure Control in Chronic Kidney Disease. J.Am.Soc.Nephrol. 17: 98-103.
Melanie K.H., G.J. Bernard, C.H. Sandra, W.C. George, & J.K. Michael. 2003. Risk Factor for Chronic Kidney Disease: A Prospective Study of 23.534 Men and Women in Washington Country. Maryland.J.Am.Soc.Nephrol. 14: 2934-2941.
Nancy J.B. & M.D. Vaughan. 2009. Cardiovascular Drugs: Angiostensin Converting Enzyme Inhibitors. America: American Heart Association.
National Institute for Health and Care Excellence, 2015, Clinical Guideline 182. Chronic kidney disease in adults: assessment and management (CG182).
Nuraeni I.N., Muhammad, L. Frans, K. Hasyim, &Satrino. 2013. Hubungan antara Volume Total Ginjal Berdasarkan Ultrasonografi dan Laju Filtrasi Glomerulus pada Penderita Penyakit Ginjal Kronik. Makassar: Fakultas Kedokteran Universitas Hassanuddin.
Nursalam, 2003, Konsep dan Penerapan Metodologi Penelitian Ilmu Keperawatan Pedoman Skripsi, Tesis, dan Instrumen Penelitian Keperawatan Edisi 2, Penerbit: Salemba Medika, Jakarta.
O’Hare A.M., A.I. Choi, D. Bertenthal, P. Bacchetti, & A.X. Garg. 2007. Age Effect Outcomes in Chronic Kidney Disease. J.Am.Soc.Nephrol. 18: 2758-2765.
Popat R., 2011, Chronic kidney disease: clinical features and renal replacement therapies. Clinical Pharmacist, 3:15-19.
Price & Wilson. 2005. Patofisiologi Konsep Klinis dan Proses-proses Penyakit. Volume 2. Jakarta: buku kedokteran EGC.
Rajiv A. 2009. Blood Preassure Components and Risk for End Stage Renal Disease and Death in Chronic Kidney Disease. J.Am.Soc.Nephrol. 4: 830-037.
Sani K. F., 2016, Metodologi Penelitian Farmasi Komunitas dan Eksperimental Dilengkapi dengan Analisis Data Program SPSS, Penerbit Deepublish, Yogyakarta.
Sica D.A. 2011. Diuretic Use in Renal Desease. Nat.Rev.Nephrol. 12: 1-10.
Sinha and Aqarwal, 2015, Thiazide Diuretics in chronic kidney desease, Springer, Vol. 3 No. 13.
Stephan R.O. & H.I. Stein. 2008. Smoking: A Risk Factor Progression of Chronic Kidney Disease and for Cardiovascular Morbidity and Mortality Renal Patients Absence of Evidence of Absence?. The American Society of Nephrology. J.Am.Soc.Nephrol. 3: 226-236.
Suhardjono E. 2007. GagalGinjalAkut. Jakarta: BalaiPenerbitFakultasKedokteranUniversitas Indonesia.
Suwitra K. 2007. Penyakit Ginjal Kronik. Buku Ajar Ilmu Penyakit Dalam.Jilid I. Edisi IV. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia.
Tandi, M., Arthur M., danFirginia M., 2014, Hubungan antara Derajat Penyakit Ginjal Kronik dengan Nilai Agregasi Trombosit di RSUP Prof. DR., R.D., Kandou Manado, Jurnal e-Biomedik (eBM), Vol.2 Nomor 2, 509-513.
Vecchio L.D., M. Procaccio, S. Vigano, & D. Cusi. 2007. Mechanisms of Disease The Role of Aldosteron in Kidney Damage and Clinical Benefits of Its Blockade. Ncpn. 3: 42-48.
Weber K.T. 2001. Aldosteron in Congestive Heart Failure. N.Engl.J.Med. 324 (23): 1689-1897.
Wim M. 2006. Age Related Increase in Plasma Urea Level and Decrease in Fractional Urea Excretion, Clinical Aplication in The Syndrome of Inapproprite Secretion of Antidiuretic Hormone. Clin.J.Am.Soc.Nephrol. 1: 909-914.
Wulandari A. 2013. Drug Therapy and Clinical Outcomes on Kidney Disorder in The Hospital University Sains Malaysia: The Effect Diuretic Drug and Combination Therapy to Clinical Outcomes. Thesis. Master of Clinical And Community Pharmacy. Padang: Pascasarjana University of Andalas.
Yuriawantini, K. Suwitra, G.R. Widiana, J.S. Loekman, & W. Sudhana. 2008. Pengaruh Spironolakton sebagai Terapi Tambahan ACE Inhibitor dan/atau Angiostensin Reseptor Blockers Terhadap Albuminuria pada Penyakit Ginjal Kronik Pradialitik Studi Klinis Acak Terkontrol Buta Ganda. J.Peny.Dalam. 9 (3): 177-183.
DOI: http://dx.doi.org/10.12928/pharmaciana.v8i1.7144
Refbacks
- There are currently no refbacks.
Copyright (c) 2021 Fathnur Sani K., Armenia Nazar, Aina Fatkhil Haque
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Office: Faculty of Pharmacy, Universitas Ahmad Dahlan
Jl. Prof. Dr. Soepomo, S.H., Janturan, Warungboto, Umbulharjo, Yogyakarta, Indonesia
Kode pos 55164
Email: pharmaciana@pharm.uad.ac.id